Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus DEXONE 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus DEXONE 4.
DEXAMETHASONE SODIUM PHOSPHATE vs DEXONE 4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a glucocorticoid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
4-20 mg IV or IM every 4-6 hours; for cerebral edema: 10 mg IV followed by 4 mg IM/IV every 6 hours; for shock: 20 mg IV initially then 2-6 mg/kg IV bolus or 40 mg IV every 2-6 hours as needed.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; however, the duration of action extends beyond the plasma half-life due to intracellular receptor-mediated effects.
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 30-40%.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Category D/X
Category C
Corticosteroid
Corticosteroid